Update on HDFN: New information on long-standing controversies

Immunohematology

Volumn 22, Issue 4, 2006, Pages 188-195

  Eder, Anne F ^a  

^a AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS ANTIBODY; RHESUS D ANTIBODY;

ALLOIMMUNIZATION; BLOOD GROUP ABO SYSTEM; BLOOD GROUP RH; CONTROLLED STUDY; EXCHANGE BLOOD TRANSFUSION; FETUS; HIGH RISK INFANT; HUMAN; HYPERBILIRUBINEMIA; IMMUNOPROPHYLAXIS; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN HEMOLYTIC DISEASE; PATIENT MONITORING; PHOTOTHERAPY; PREGNANCY; PRIORITY JOURNAL; REVIEW;

BLOOD TRANSFUSION, INTRAUTERINE; ERYTHROBLASTOSIS, FETAL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RH-HR BLOOD-GROUP SYSTEM;

EID: 33846922482     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Eder, AF, Manno, C.S. Alloimmune hemolytic disease of the fetus and newborn. In Wintrobe's Clinical Hematology, 11th ed. (Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader BE, (eds). Philadelphia, PA: Lippincott, Williams & Wilkins, 2004.
2. Moise KJ. Red blood cell alloimmunization in pregnancy. Semin Hematol 2005; 42:169-78.
3. Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. J Am Med Assoc 1991;265:3270-4.
4. Joseph KS, Kramer MS. The decline in Rh hemolytic disease: should Rh prophylaxis get all the credit? Am J Public Health 1998;88:209-15.
5. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2002. Natl Vital Stat Rep 52:1-116, 2002.
6. Reid ME, Lomas-Francis C. The blood group antigen factsbook. 2nd ed. San Diego, CA: Academic Press, 2004.
7. Moise KJ. Non-anti-D antibodies in red-cell alloimmunization. Eur J Obstet Gynecol Reprod Biol 2000;92:75-81.
8. Heddle NM, Klama L, Frassetto R, et al. A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion 1993;23:217-20.
9. Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R. Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 1997;89:272-5.
10. Van der Schoot CE, Tax GH, Rijnders RJ, de Haas M, Christiaens GC. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003;17:31-44.
11. van Kamp IL, Klumper FJ, Oepkes D, et al. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gyecol 2005;192:171-7.
12. Prevention of RhD alloimmunization. ACOG Practice Bulletin Number 4. Washington, DC: American College of Obstetricians and Gynecologists, May 1999.
13. Judd WJ. Practice guidelines for prenatal and perinatal immunohematology, revisited. Transfusion 2001;41:1445-52.
14. Garratty G, Do we need to be more concerned about weak D antigens? Transfusion 2005;45:97-101.
15. Denomme GA, Wagner FF, Fernandes BJ, Li W, Flegel WA, Partial D, weak D types and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005; 45:1554-60.
16. Cannon M, Pierce R, Taber EB, Schucker J. Fatal hydrops fetalis caused by anti-D in a mother with partial D. Obstet Gynecol 2003;102:1143-5.
17. Comments: Obstet Gynecol 2004;104:193-5.
18. Domen RE. Polices and procedures related to weak D phenotype testing and Rh immune globulin administration. Arch Pathol Lab Med 2000;124:1118-21.
19. AABB Standards for Blood Banks and Transfusion Services, 23rd ed. Bethesda, MD: AABB, 2004.
20. de Silva M, Engelfriet CP, Reesink HW, Current status of immunoprophylaxis with anti-D immunoglobulin. Vox Sang 2003;85:328-37.
21. Ness PM, Baldwin ML, Niebyl JR. Clinical high-risk designation does not predict excess fetal-maternal hemorrhage. Am J Obstet Gynecol 1987;156:154-8.
22. Pourbabak S, Rund CR, Crookston KP. Three cases of massive fetomaternal hemorrhage presenting without clinical suspicion. Arch Pathol Lab Med 2004;128:463-5.
23. Means ND, Bandarenko N, Moise JR KJ, Brecher ME. Likelihood of D heterozygosity in Mestizo Mexicans and Mexican Americans. Immunohematol 2001;17:22-3.
24. Singleton BK, Green CA, Avent ND, Martin PG, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype. Blood 2000;95:12-18.
25. Kim JY, Kim SY, Kim CA, Yon GS, Park SS. Molecular characterization of D- Korean persons: development of a diagnostic strategy. Transfusion 2005;45:345-52.
26. Heckerling PS, Verp MS. Amniocentesis or chorionic villus sampling for prenatal genetic testing: A decision analysis. J Clin Epidemiol 1991;44:457-70.
27. Bianchi DW, Avent ND, Costa JM, Van der Schoot CE. Noninvasive prenatal diagnosis of fetal Rhesus D: ready for prime(r) time. Obstet Gynecol 2005;106:682-3.
28. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci 1996;93:705-8.
29. Oepkes D, Seaward PG, Vandenbussche F, Windrim R, et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med 2006;355:156-64.
30. Vaughan JI, Manning M, Warwick RM, et al. Inhibition of erythroid progenitor cells by anti-K antibodies in fetal alloimmune anemia. N Engl J Med 1998;338:798-803.
31. Denomme GA, Ryan G, Seaward PGR, Kelly EN, Fernandes BJ. Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17. Transfusion 2004;44:1357-60.
32. Herschel M, Karrison T, Wen M, et al. Isoimmunization is unlikely to be the cause of hemolysis in ABO-incompatible but direct antigen test-negative neonates. Pediatrics 2002;110:127-30.
33. Dinesh D. Review of positive direct antiglobulin tests found on cord blood sampling. J Pediatr Child Health. 2005;41:504-7.
34. Biondi CS, Cotorruelo CM, Ensinck A, Racca LL, Racca AL. Use of the erythrophagocytosis assay for predicting the clinical consequences of immune blood destruction. Clin Lab 2004;50:265-70.
35. American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia, Clinical Practice Guideline: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316.
36. Newman TB, Liljestrand P, Jeremy RJ, Ferriero DM, et al. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Eng J Med 2006;354:1889-900.